Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Cellid is a research and development bioventure company. The company is developing immunotherapeutic vaccines, CeliVax. The CeliVax is a personalized vaccine which uses patient's own cells.

Riken Corp. engages in the manufacture and sale of engine and vehicular components. It operates through the Automotive and Machinery Parts, and Others segments. The Automotive and Machinery Parts segment deals with the company's core products such as piston rings, camshafts, seal rings for transmissions, high-grade cast iron products, and valve lifters. The Others segment includes plumbing equipment business, Electromagnetic Compatibility (EMC) business, and thermal engineering business, The company was founded by Masatoshi Okochi in November 1927 and is headquartered in Tokyo, Japan.

Part of MOH Holdings Pte Ltd., Singapore Health Services Pte Ltd. is a Singaporean company located in Singapore. The firm provides medical services. Ivy Ng is the CEO, in this role since 2012.

Anthrogenesis, based in Cedar Knolls, New Jersey, is a biotherapeutics company that has developed proprietary methods for collecting, processing and storing stem cells and other valuable biomaterials derived from human placental tissue. Anthrogenesis is focused on developing and delivering therapies using stem cells sourced from human placental tissue to treat cancers and immunological, metabolic and inflammatory diseases. Anthrogenesis has demonstrated that the human placenta is an abundant source of biotherapies, including early stage stem cells and other biomaterials for organ and tissue repair. Anthrogenesis also operates Lifebank, a state-licensed blood bank that banks stem cell transplant units derived from placental tissue and in some cases, blood from the umbilical cord that is collected immediately after birth.

Kirin Brewery Co., Ltd. engages in the manufacture of alcoholic beverages. Its products include beer, sparkling liquor, chuhai, gin, and whiskey. The company was founded in 1901 and is headquartered in Tokyo, Japan.

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.

Fuhe Biomedical provides a number of immune system related services, performs immune function analysis in the testing laboratory and conducts customized immune function related analysis projects with major specialist clinics and medical institutions. Their services include immune function analysis, circulating tumor cell analysis, special management methods, cell process foundry, immune cell storage and commissioned analysis services.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

ONK Therapeutics is an innovative cell therapy company dedicated to developing the next generation of off-the-shelf, optimally engineered natural killer (NK) cell therapies targeting both hematological malignancies and solid tumors.

REGiMMUNE Corporation is a private biopharmaceutical company developing innovative solutions for treating immune disorders caused by nonspecific and/or excessive immune reactions. REGiMMUNE uses its proprietary technology platform, reVax (reverse vaccination), to target immune tolerance against specific disease-causing antigens through induction of regulatory T cells (Treg). This technology has potential applications in a number of immune system disorders and diseases including Graft versus Host Disease (GvHD), type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE). Currently, the company has one clinical-stage compound in a Phase I/II trial in the United States (RGI-2001) as a treatment for GvHD associated with hematopoietic stem cell transplantation and has a second product in preclinical development (RGI-3001) as a new treatment for T1DM. In addition, it has a number of well-differentiated compounds in its research-stage pipeline. In healthy individuals, the normal immune system works to protect humans from disease-causing viruses, bacterium, and cancers; or foreign antigens such as peanuts, wheat and tree pollens. Conventional immunosuppressants have several significant side effects associated with long-term administration including risk of infection, toxicity and relapse. Products developed with ReVax technology are expected to reduce or eliminate such side effects as well as reduce long-term treatment.

NKMAX is a biotechnology company that develops immune cell therapy that can treat incurable human diseases, including cancer. They specialise in immune cells and provide immune healthcare solutions from diagnosis to treatment. They provide a precision immunodiagnostic kit that measures immunity based on research on NK cells.

Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of hematological and solid cancers. Its platform creates and develops next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer as well as develop potent, safe, and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells that enable doctors to safely channel the immune system's response towards tumors.

GC Cell Corp. engages in the research and development of cell curing agents and in the transport and sale of consignment inspection samples. It offers cell therapy products, cell banking, clinical laboratory services, clinical trials and bio logistics. The company was founded on June 21, 2011 and is headquartered in Yongin-si, South Korea.

UCLB is the commercialisation company of UCL and its partner NHS Trusts. They bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives. UCLB the access point to the wealth of innovation and intellectual property emanating from UCL and partner hospitals including University College Hospital, Great Ormond Street Hospital, Royal Free Hospital and Moorfields Eye Hospital. They offer a number of services to assist the technology development process, from consultancy through to collaborative research, IP licensing and the creation of spinout companies and joint ventures to maximise the commercial potential of new discoveries, materials and processes.